FDA Approval
Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Jazz Pharmaceuticals
PR-M11-18-NI-006Nov 02, 2018
FDA Approval
Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Jazz Pharmaceuticals
PR-M10-18-NI-100Oct 30, 2018